Proceedings of the National Academy of Sciences of the United States of America · 2023
Cryo-EM structures of human GPR34 enable the identification of selective antagonists.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Anjie, Yong Xihao, Zhang Changbin, Lin Guifeng, Jia Guowen, Zhao Chang, Wang Xin, Hao Yize, Wang Yifei, Zhou Pei, Yang Xin, Deng Yue, Wu Chao, Chen Yujiao, Zhu Jiawei, Tang Xiaodi, Liu Jingming, Zhang Shiyu, Zhang Jiahao, Xu Zheng, Hu Qian, Zhao Jinlong, Yue Yuting, Yan Wei, Su Zhaoming, Wei Yuquan, Zhou Rongbin, Dong Haohao, Shao Zhenhua, Yang Shengyong
Аннотация
GPR34 is a functional G-protein-coupled receptor of Lysophosphatidylserine (LysoPS), and has pathogenic roles in numerous diseases, yet remains poorly targeted. We herein report a cryo-electron microscopy (cryo-EM) structure of GPR34 bound with LysoPS (18:1) and Gi protein, revealing a unique ligand recognition mode with the negatively charged head group of LysoPS occupying a polar cavity formed by TM3, 6 and 7, and the hydrophobic tail of LysoPS residing in a lateral open hydrophobic groove formed by TM3-5. Virtual screening and subsequent structural optimization led to the identification of a highly potent and selective antagonist (YL-365). Design of fusion proteins allowed successful determination of the challenging cryo-EM structure of the inactive GPR34 complexed with YL-365, which revealed the competitive binding of YL-365 in a portion of the orthosteric binding pocket of GPR34 and the antagonist-binding-induced allostery in the receptor, implicating the inhibition mechanism of YL-365. Moreover, YL-365 displayed excellent activity in a neuropathic pain model without obvious toxicity. Collectively, this study offers mechanistic insights into the endogenous agonist recognition and antagonist inhibition of GPR34, and provides proof of concept that targeting GPR34 represents a promising strategy for disease treatment.